STOCK TITAN

CECORS (CEOS) Stock News, Aug 2022-May 2023

CEOS OTC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.45%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
partnership
Rhea-AI Summary

CeCors has announced its acquisition of VetComm Corp., marking its entry into the multibillion-dollar veterans benefits industry. The acquisition includes the issuance of unregistered shares to VetComm's shareholders. CeCors aims to limit shareholder dilution by returning a portion of shares owned by executives to the treasury, which will be canceled and reissued to VetComm's founder, Kate Monroe. VetComm, founded by a U.S. Marine Corps veteran, assists veterans in accessing underutilized benefits, potentially unlocking billions in unclaimed compensation. The acquisition is expected to enhance CeCors' offering and market reach, creating long-term value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
-
Rhea-AI Summary

CeCors has signed a binding letter of intent (LOI) with VetComm Corp, a company focused on assisting U.S. veterans in claiming unutilized benefits. This partnership aims to integrate CeCors' PsyKey Live app into VetComm's platform, potentially enhancing mental wellness support for veterans. VetComm, founded by U.S. Marine Corps veteran Kate Monroe, has a database of over 250,000 veterans and adds 2,000 daily. The collaboration seeks to address the unclaimed billions owed to veterans while promoting their entitled benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
-
Rhea-AI Summary

CeCors, Inc. (OTC PINK: CEOS) has appointed Dr. Michael J. McCarthy to its scientific and medical advisory board through its subsidiary, PsyKey Inc. With over 35 years in biopharmaceutical consulting, Dr. McCarthy specializes in high-impact pharmaceuticals and securing biomedical patents. His previous work at Scripps Research involved groundbreaking technologies in therapeutic applications. Dr. McCarthy's expertise is expected to enhance PsyKey's product development efforts, particularly in the area of mycology-based wellness products, which focus on the health benefits of mushrooms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
management
Rhea-AI Summary

CeCors, Inc. (OTC PINK: CEOS) has appointed John Gustin as head of global business development through its subsidiary PsyKey Inc. Gustin brings over 30 years of experience in nutritional companies and patented several health formulations. His expertise aims to enhance PsyKey's competitive advantage and expand its market presence. Gustin expressed enthusiasm about PsyKey's potential in the evolving functional wellness industry. PsyKey focuses on mycology-based wellness solutions, emphasizing inclusivity and access to healthcare services for optimal consumer health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.84%
Tags
none
-
Rhea-AI Summary

CeCors, Inc. (OTC PINK: CEOS) announced a distribution agreement with Hygeia, LLC to enhance the national distribution of its functional product lines through its subsidiary PsyKey Inc. The partnership aims to provide access to thousands of retail locations nationwide, facilitating rapid distribution and the introduction of new products. Hygeia specializes in lifestyle and wellness products and has established relationships with major retailers and wholesalers. This collaboration is expected to bolster brand visibility and sales growth for CeCors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.05%
Tags
none
-
News
Rhea-AI Summary

CeCors, Inc. (OTC PINK: CEOS) announced significant growth during fiscal 2022, driven by its acquisition of PsyKey. The company launched its first product line, PsyKey Functional Mushroom Infused coffees, which received positive feedback and bulk orders, signaling expected revenue growth starting Q3. CeCors is also finalizing its acquisition of Nutra-Rox LLC, enhancing its portfolio with innovative delivery technologies. Additionally, CeCors aims to remove its 'shell' status, improving market transparency and liquidity for shareholders, emphasizing sustained growth and value creation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
Rhea-AI Summary

CeCors, Inc. (OTC PINK:CEOS) announces the launch of its monthly coffee subscription services through its subsidiary, PsyKey Inc.. Targeted for corporate and individual consumers, the subscription aims to tap into a rapidly growing retail segment projected to exceed $65 billion globally by 2022. The corporate service will offer custom-designed subscriptions, while the individual program is set to launch in September 2022. These services utilize premium, ethically sourced Arabica coffee and functional mushrooms to promote convenience and quality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none

FAQ

What is the current stock price of CECORS (CEOS)?

CECORS (CEOS) last closed at $0.0055.

What is the market cap of CECORS (CEOS)?

The market cap of CECORS (CEOS) is approximately $1.8M.